Approved Product Dossiers

What goes in Section 1?

Section 1.0B Highlights and Overview

Include

Executive Summary – Clinical and Economic Value of the Product

- Clinical Benefits
- Economic Benefits
- Conclusions



"…principal opportunity for a manufacturer to briefly summarize the value of its product."

"…the manufacturer should articulate a value argument to justify these expected expenditures in the context of its anticipated effects on the clinical evidence, health outcomes, and the economic consequences for the health care system."

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 1.0B Highlights and Overview

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Include

1.1B Clinical Benefits	Efficacy and effectiveness
	Comparative effectiveness
	Safety and tolerability
	Shortcomings of current available treatment and unmet need
1.2B Economic Benefits	Cost per unit
	Context of proposed cost
	Shortcomings of other therapies
1.3B Conclusions	Summarize value
	Highlight clinical and economic advantages
	Describe uniqueness of product
	State the expected effect of product



References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Approved Product Dossiers

What goes in Section 2?

Section 2.1B Product Description

Include

- Generic and brand name and therapeutic class
- All dosage forms, including strengths and package sizes
- National Drug Code (NDC) for all formulations
- Average sales price (ASP) and wholesale acquisition cost (WAC) per unit size
- American Hospital Formulary Service (AFHS) or other drug classification
- FDA-approved indications and date approval was granted
- Pharmacology
- Pharmacokinetics/pharmacodynamics
- Contraindications/warning/precautions/adverse effects
- Special populations
- Interactions
- Dosing and administration
- Access
- Coprescribed/concomitant therapies
- Effect on quality measures

Section 2.1.1B Product Comparison

Include

Comparison of Prescribing Information with primary comparator products in the same therapeutic area

- Safety
- Efficacy
- Dosing
- Indications
- Pharmacokinetics/pharmacodynamics
- Adverse effects
- Warnings
- Contraindications
- Interactions

Statements about why comparators were selected

Formatted in tables

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.2B Place of Product in Therapy

Include

- 2.2.1B Disease Description
- 2.2.2B Approaches to Treatment



Content should be:

- Brief
- Presented in tables, bulleted lists, or other easy-to-read format
- Not duplicated in 3.0B, 4.0B, or 5.0B

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.2.1B Disease Description

Include	"a good overall sense of the disease."
	Epidemiology and risk factors
	Pathophysiology
	Clinical presentation
	Societal, humanistic, and economic burden
Content should be:	Brief
	Include disease and characteristics of patients
	Brief summary of information from the literature for each topic

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.2.2B Approaches to Treatment

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Key questions

- How is the disease currently treated?
- How does new product fit into standard therapy?

Summarize current literature

- Current approaches to treatments
- Place and uses of product
- Appropriate care settings
- Heterogeneity of treatment effect
- Ancillary disease or care management intervention strategies
- Post-marketing obligations required by FDA
- Ongoing post-approval monitoring of drug safety and adverse events
- Expected outcomes of therapy

Section 2.3B Evidence for Companion Diagnostic Tests

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Drug Dossier with Companion Diagnostic Test

- When CDT is co-developed with drug
- When CDT is required by FDA

Include Sections 2.3.1B and 2.3.3B

Companion Diagnostic Test Dossier

- When CDT is not tied to drug
- When CDT is not owned by the manufacturer

Include Sections 1.0B, 2.3.1B, 2.3.2B, 2.3.3B, 4.0B, and 5.0B

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.3.1B Product Information for Companion Diagnostic Tests

Include

Generic name, brand name, manufacturer, or clinical laboratory
Type of test
Test target
Date of FDA clearance or approval
Intended use / clinical basis for CDT
Indication and target population; prevalence of disease/condition and CDT variant
Place of CDT in drug therapy
Contraindications, warning / precautions, interactions relative to CDT use
Alternative tests and options available; relative advantages and disadvantages
Other key assumptions and their rationale
Supporting clinical and economic evidence for the test, using ACCE framework
Packaging description, regulatory codes, classification, and identifiers
Billing and reimbursement codes, price
Copy of product label or package insert



Drug Dossier with CDT

CDT Dossier

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.3.1B Product Information for Companion Diagnostic Tests

Supporting clinical and economic evidence for the test, using ACCE framework

Analytical validity

- Accuracy
- Specificity
- Sensitivity
- Precision

Clinical validity

- Positive predictive value
- Negative predictive value
- Thresholds used to separate positive from negative result
- Populations tested and validated

Clinical utility

- Interventions
- Efficacy/effectiveness and safety
- Changes in patient outcomes
- Quantitative risk-benefit decision-analytic modeling

Economic value

- Expected differences in costs and outcomes
- Economic analysis
- Incremental costs per diagnosis, treatment modification, events avoided, life-years saved, quality-adjusted life-years gained



Drug Dossier with CDT

CDT Dossier

Section 2.3.2B Place of CDT in Clinical Practice

Include

- Disease Description
  - Epidemiology and relevant risk factors
  - Pathophysiology
  - Clinical presentation
  - Societal and economic impact of disease
- Approaches to Treatment
  - Diagnosis
  - Anticipated use of text in patient management
  - Prognosis
  - Relevant clinical practice guidelines



CDT Dossier

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.3.3B Supporting Clinical Data for CDT

Drug Dossier with Companion Diagnostic Test

- Studies pertaining to the CDT



Drug Dossier with CDT

Companion Diagnostic Test Dossier

- All clinical trials that include CDT

CDT Dossier

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.3.3B CDT Supporting Clinical Data for

Submit summaries of key studies conducted:

- Analytical validation studies
- Clinical validation studies
- Clinical utility studies
- Outcomes studies
- Safety studies

Include whether they are published or not

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 2.3.3B CDT Supporting Clinical Data for

Evidence in summaries should include:

- Setting and location of study
- Study design, research questions
- Inclusion and exclusion criteria
- Patient characteristics
- Intervention and control group
- Patient follow-up procedures
- Clinical outcome measures
- Outcomes evaluated
- Primary versus secondary study endpoints
- Other results/outcomes reported
- Principal findings
- Statistical significance of outcomes and power calculations
- Variation of outcomes instrument
- Compliance behavior
- Generalizability of the population treated
- Relevance to enrolled population
- Publication citations / references used
- Access information for studies registered in a public trial registry

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Approved Product Dossiers

What goes in Section 3?

Section 3.0B Clinical Evidence

Include

- Prospective clinical studies
  - Randomized clinical trials
  - Prospective observational studies
  - Registries
- Retrospective studies
  - Conducted using existing data from chart reviews, medical and pharmacy claims, electronic medical records or, other novel sources of data
- Studies that synthesize the above studies
  - Indirect treatment comparisons
  - Meta-analyses of the product and comparators

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 3.1B Study Summaries

Include

Publication citations, study name, clinicaltrails.gov ID number, funding source
Objective, location, and study start and completion dates
Trial design, randomization, blinding procedures
Setting, inclusion and exclusion criteria
Baseline patient characteristics and demographics
Drop-out rates and procedures for handling
Treatments, interventions, dosage regimens, washout period, concomitant therapies
Clinical outcomes evaluated, measured, and collected; primary vs secondary endpoints; prespecified vs post hoc
Measures of effect, statistical significance, power calculations
Validation of outcomes instruments
Generalizability of population treated
Study limitations



References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 3.2B Evidence Tables

Include
Citation
Treatments
Sample size and length of follow-up
Inclusion and exclusion criteria
Design
Primary endpoints
Secondary endpoints
Results
Statistical significance



Unlike the rest of the document, these will need to be in landscape rather than portrait. More liberal use of abbreviations will also assist in making it all fit on the page.

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Approved Product Dossiers

What goes in Section 4?

Section 4.0B Economic Value and Modeling Report

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Include

- 4.1B Modeling Overview
  - Overview of rationale, approach, and suggested methods for developing economic models.
- 4.2B Cost-effectiveness Analysis
- 4.3B Budget Impact Models
- 4.4B Modeling Report and Interactive Model



References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.1B Modeling Overview

Include

- 4.1B Modeling Overview
  - Intent: quantify risk-benefit tradeoff of product, product's economic value
  - 4.1.1B Use of Modeling for Decision-Making
  - 4.1.2B Type of Models
    - Cost-effectiveness Models
    - Budget Impact Models
    - Financial Models
  - 4.1.3B Other Considerations



References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.2B Cost-effectiveness Analysis

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Include 4.2.1B Approach and Framework

Guidelines

Framework should consider recommendations from guidelines, such as The Professional Society for Health Economics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM) Modeling Good Research Practices Task Force.

Analytic Framework

Analyses that value outcomes by assessing clinical events, life expectancy, and quality-adjustment life-years.

Modeling Technique

- Decision Trees
- Markov Models
- Patient-level Simulation

Perspective and Timeframe



References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.2B Cost-effectiveness Analysis

Include

4.2.2B Data Sources

- Drug Effectiveness
- Drug Safety Data
- Economic Data
- Utilities
- Demographic and Practice Pattern Data
- Surrogate Markers
- Expert Opinion
- Efficacy vs Effectiveness

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.2B Cost-effectiveness Analysis

Include

4.2.3B Conduct

Base-case Estimates

- Expected clinical and economic outcomes
- Incremental costs and effectiveness
- Differences in absolute risk of events
- Health care costs vs drug costs
- Clinical risk-benefit tradeoffs

Sensitivity Analysis

- Univariate and probabilistic sensitivity analyses
- Confidence levels (95%)
- Tornado diagrams
- 3-5 parameters / 2-3 assumptions with greatest effect on results
- Scenario analyses
- Cost-effectiveness scatter plots and acceptability curves

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.3B Budget Impact Models

Include

4.3.1B Approach and Framework

Guidelines

Framework should follow guidelines provided by The Professional Society for Health Economics and Outcomes Research (ISPOR)

Perspective and Timeframe

Perspective: Health Care Decision Maker

Timeframe: 1-5 years

Population

Target: All patients eligible to receive new intervention during timeframe

4.3.2B Data Sources

Base-case model: representative of US population or general commercial or Medicaid population.

4.3.3B Conduct



References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.4B Modeling Report and Interactive Model

Include

4.4.1B Transparency

High-level overview of model structure, components, and outputs

Detailed documentation for users to evaluate technical aspects of model

Audience: non-health economist



4.4.2B Modeling Report Format

4.4.3B Interactive Model

Model Characteristics

Spreadsheet

Model Accessibility

Interactive model available electronically

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Section 4.4.2B Modeling Report Format

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Include

4.4.2B Modeling Report Format

- Introduction/Background
- Methods
- Results
- Limitations
- Discussion

- Figure 1: structure of model
- Table 1: list of all model inputs, including references
- Table 2: list of model assumptions
- Table 3: disaggregated results
  - Projected clinical events
  - Life expectancy and quality-adjusted life-years estimates
  - Total health care costs
  - Cost of implementing therapy
  - Model results
- Figure 2: one-way sensitivity analyses on all model inputs
  - Model input or assumptions that drive difference in costs, effects, and incremental cost-effectiveness
  - If appropriate, present multi-way sensitivity analyses

Consider following the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Guidance

References: AMCP Format Executive Committee. *AMCP Format for Formulary Submissions: Guidance on Submission of Pre-approval and Post-approval Clinical and Economic Information and Evidence.* Accessed January 29, 2020. https://www.amcp.org/Resource-Center/format-formulary-submissions/AMCP-Format-for-Formulary-Submissions-4.1

Approved Product Dossiers

What goes in Section 5?

Section 5.0B Additional Supporting Evidence

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Include

All other types of evidence and studies that support the use and value of the product but that do not fit into Section 3

- 5.1B Clinical Practice Guidelines
- 5.2B HTAs and Systemic Reviews
- 5.3B Compendia
  - Summarize available information; may not be able to provide copy
- 5.4B Other Economic or Outcomes Evidence
  - Provide if available
- 5.5B Effect on Quality
  - Provide if available
- 5.6B Other Evidence or Information
  - Provide if available



Section 5.1B Clinical Practice Guidelines

Include	Clinical practice guidelines, position statements, consensus statements, clinical pathways
	Medical societies, government agencies, national or international organizations
	Specific to product, its comparators, and disease state
	Provide a copy or links to original guidelines



Section 5.2B HTAs and Systemic Reviews

Med COMMUNICATIONS
The Right Partner. The Right Resource.

Include

Cochrane Collaboration systematic reviews

Formal systematic review published by peer-reviewed journals

Evidence reviews by the Agency for Healthcare Research and Quality (AHRQ) or the Patient-Centered Outcomes Research Institute (PCORI)

Reports from the Institute for Clinical and Economic Review (ICER)

HTAs from recognized public or private organizations:

- National Institute of Clinical Evidence (NICE)
- Canadian Agency for Drugs and Technologies in Health (CADTH)



Approved Product Dossiers

What goes in Section 6?

Section 6.0B Dossier Appendices

Include

6.1.B References Contained in Dossier

Include citations and links to original sources if they are freely available.

6.2B Economic Models

Include actual economic models.

6.3B Product Prescribing Information

Include label or PI.

6.4B Patient Information

Include patient information, such as patient PI.

6.5B Material Safety Data Sheet

Include Material Safety Data Sheet.